These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 19954432

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ, Almond HR, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.
    J Med Chem; 2005 Mar 24; 48(6):1984-2008. PubMed ID: 15771442
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
    Burke FM, Warnock M, Schmaier AH, Mosberg HI.
    Chem Biol Drug Des; 2006 Nov 24; 68(5):235-8. PubMed ID: 17177882
    [Abstract] [Full Text] [Related]

  • 5. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A, Mennecier P, Lila C, de Nanteuil G, Verbeuren TJ.
    Thromb Haemost; 1997 Oct 24; 78(4):1221-7. PubMed ID: 9364988
    [Abstract] [Full Text] [Related]

  • 6. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
    Alexopoulos K, Fatseas P, Melissari E, Vlahakos D, Roumelioti P, Mavromoustakos T, Mihailescu S, Paredes-Carbajal MC, Mascher D, Matsoukas J.
    J Med Chem; 2004 Jun 17; 47(13):3338-52. PubMed ID: 15189031
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of potent thrombin receptor antagonist peptides.
    Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM.
    J Med Chem; 1996 Dec 06; 39(25):4879-87. PubMed ID: 8960546
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and SAR of thrombin inhibitors incorporating a novel 4-amino-morpholinone sscaffold: analysis of X-ray crystal structure of enzyme inhibitor complex.
    Nilsson JW, Kvarnström I, Musil D, Nilsson I, Samulesson B.
    J Med Chem; 2003 Sep 11; 46(19):3985-4001. PubMed ID: 12954052
    [Abstract] [Full Text] [Related]

  • 11. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY, Sall DJ, Briggs SL, Clawson DK, Zhang M, Smith GF, Schevitz RW.
    Protein Sci; 2000 Jan 11; 9(1):29-36. PubMed ID: 10739244
    [Abstract] [Full Text] [Related]

  • 12. Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
    Malikayil JA, Burkhart JP, Schreuder HA, Broersma RJ, Tardif C, Kutcher LW, Mehdi S, Schatzman GL, Neises B, Peet NP.
    Biochemistry; 1997 Feb 04; 36(5):1034-40. PubMed ID: 9033393
    [Abstract] [Full Text] [Related]

  • 13. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
    Slon-Usakiewicz JJ, Sivaraman J, Li Y, Cygler M, Konishi Y.
    Biochemistry; 2000 Mar 07; 39(9):2384-91. PubMed ID: 10694407
    [Abstract] [Full Text] [Related]

  • 14. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.
    Orning L, Fischer PM, Hu CK, Agner E, Engebretsen M, Husbyn M, Petersen LB, Orvim U, Llinas M, Sakariassen KS.
    Thromb Haemost; 2002 Jan 07; 87(1):13-21. PubMed ID: 11848442
    [Abstract] [Full Text] [Related]

  • 15. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
    Tucker TJ, Brady SF, Lumma WC, Lewis SD, Gardell SJ, Naylor-Olsen AM, Yan Y, Sisko JT, Stauffer KJ, Lucas BJ, Lynch JJ, Cook JJ, Stranieri MT, Holahan MA, Lyle EA, Baskin EP, Chen IW, Dancheck KB, Krueger JA, Cooper CM, Vacca JP.
    J Med Chem; 1998 Aug 13; 41(17):3210-9. PubMed ID: 9703466
    [Abstract] [Full Text] [Related]

  • 16. Peptides and pseudopeptides incorporating D-Phe-Pro-Arg and Arg-Gly-Asp lead sequences as potential antithrombotic agents.
    Ilas J, Hudecz F, Süli-Vargha H, Kikelj D.
    J Pept Sci; 2008 Aug 13; 14(8):946-53. PubMed ID: 18383437
    [Abstract] [Full Text] [Related]

  • 17. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K, Park CW, Jung WH, Park HD, Lee SH, Chung KH, Park SK, Kwon OH, Kang M, Park DH, Lee SK, Kim EE, Yoon SK, Kim A.
    J Med Chem; 2003 Aug 14; 46(17):3612-22. PubMed ID: 12904065
    [Abstract] [Full Text] [Related]

  • 18. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B, Muley L, Heine A, Smolinski M, Hangauer D, Klebe G.
    J Mol Biol; 2009 Aug 21; 391(3):552-64. PubMed ID: 19520086
    [Abstract] [Full Text] [Related]

  • 19. [Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation].
    Pastorova VE, Liapina LA, Cherkasova KA, Ashmarin IP.
    Usp Fiziol Nauk; 1999 Aug 21; 30(2):80-91. PubMed ID: 10420478
    [Abstract] [Full Text] [Related]

  • 20. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.
    Zdanov A, Wu S, DiMaio J, Konishi Y, Li Y, Wu X, Edwards BF, Martin PD, Cygler M.
    Proteins; 1993 Nov 21; 17(3):252-65. PubMed ID: 8272424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.